Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€5.02

€5.02

0.490%
0.0245
0.490%
-
 
09:35 / Tradegate WKN: A2QL01 / Name: Stellantis / Stock / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Stellantis N.V. Stock

Stellantis N.V. gained 0.490% compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Stellantis N.V. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Stellantis N.V. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot AI-generated

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2026-07-26

Stellantis’s FY2025 results mark a striking break from the group’s recent history. After several years of solid profitability—net income averaged over €6.5 billion across the prior four years—the company recorded a net loss exceeding €22 billion, with revenue slipping only modestly to just over €153 billion. The overall trajectory suggests that a confluence of operational setbacks and significant non-cash charges overwhelmed what was previously a stable earnings profile.

The most visible distortion sits in the income statement. Gross margin flipped to a negative 1.4%, down from 13% a year earlier, implying that the cost of sales alone outstripped revenue. Selling, general and administrative expenses remained substantial, but it is the scale of restructuring expenses (over €900 million) and a €1.3 billion share of losses from equity-method investments that compounded the pressure. As a result, the operating margin collapsed to roughly -17% and net margin to around -14.5%. The deterioration appears to have been accelerated by large non-cash items—provisions of over €11 billion and “other non-cash adjustments” of nearly €11 billion feature prominently in the cash flow reconciliation—which could indicate substantial write-downs or forward-looking charges tied to the group’s strategic realignment.

The balance sheet reflects this shock. Equity contracted by about 34% year-on-year, falling to roughly €54 billion, while total assets remained broadly stable near €195 billion. Debt-to-equity consequently rose to 0.59 from 0.24 in the preceding year, though absolute net debt remains relatively modest at €1.68 billion. That said, liquidity is thin: the current ratio barely exceeds 1.0, and the quick ratio sits below 0.75. Inventories of over €22 billion represent a sizable portion of current assets, and trade payables of around €30 billion could place pressure on working capital if sales momentum weakens further.